PLRX News and Press, Pliant Therapeutics Inc.

New Fortress Energy Inc. (NFE) is expected to report $-1.08 for Q4 2025 Design Therapeutics Inc. (DSGN) is expected to report $-0.38 for Q4 2025 Beta Technologies Inc. Class A (BETA) is expected to report $-0.52 for Q4 2025 Yext Inc. (YEXT) is expected to report $0.06 for Q4 2026 ...

2026-03-06 08:00:00 ET Showcase Intro In February, we welcomed 17 new analysts who published their first-ever article on Seeking Alpha. In this article, our editors highlight some of the best ideas from these new analysts and introduce them.... Read the full article on Seeking...

Astrana Health Inc. (ASTH) is expected to report $0.15 for Q4 2025 Sealed Air Corporation (SEE) is expected to report $0.72 for Q4 2025 Surgery Partners Inc. (SGRY) is expected to report $0.27 for Q4 2025 Kuehne + Nagel International AG ADR (KHNGY) is expected to report $0.4 for Q4 20...

2026-02-24 01:28:45 ET Editor's note: Seeking Alpha is proud to welcome Mosiv Capital as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium...

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Oppenheimer 36th Annual Healthcare Life...

One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment of 15 months Company to accelerate development of PLN-101095 with initiation...

SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Piper Sandler 37 th Annual Healthcare Confe...

2025-11-06 18:03:11 ET More on Pliant Therapeutics Allogene, Pliant down as J.P. Morgan cuts to Underweight on uncertain outlook Seeking Alpha’s Quant Rating on Pliant Therapeutics Historical earnings data for Pliant Therapeutics Financial information ...

Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology...

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...